Shots:

• The first patient has been dosed in the P-III frontMIND study evaluating tafasitamab + lenalidomide + R-CHOP vs R-CHOP alone as a 1L treatment for high-intermediate and high-risk ~880 patients with DLBCL
• The 1EP of the study is PFS and 2EP include event-free survival- OS- metabolic CRR- and ORR
• The preliminary data from the ongoing P-Ib firstMIND study showed a 91.1% response rate across both arms in a patient population- and combination therapy showed a tolerable profile. The results will further support the frontMIND study for the combination therapy

  Ref: Business Wire | Image: Business Wire